Morphoceuticals
Jim Jenson is the CEO and Director at Morphoceuticals, Inc. Jim is also a Strategic Adviser and Founding CEO at CytoSite Biopharma Inc. Additionally, Jim is a Founding Member of the BioPharma Executive Council and The BioPharma Hub. Jim has experience as the Founding CEO at Sabik Medical Inc., Dicerna Pharmaceuticals, Inc., Zapaq, Inc./CoMentis, Inc., Polaris Pharmaceuticals, and as the VP Research at Procept. Jim has also served as the Director Protein Chemistry and Chairman SAB at Triton Biosciences/Berlex Biosciences/Schering AG and as a Research Investigator and Head of the Molecular Immunology Group at Hoffmann-LaRoche. Jim holds a BA in Biology from Macalester College and a PhD in Biology/Biochemistry from Cornell University.
This person is not in any teams
Morphoceuticals
Morphoceuticals Inc. is a biotechnology company co-founded by Drs. Levin and Kaplan and funded by Juvenescence Ltd. Morphoceuticals is pioneering bioelectric approaches to access anatomical programming that is a core component of our biological operating system. Using proprietary combinations of ion channel and gap junction modulators, we are focused on inducing limb regeneration, improving amputation stump health, promoting organ regeneration, and the treatment of channelopathies.